VERU Veru, Inc.

Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.

Company profile

Ticker

VERU

Exchange

NASDAQ

Website

www.verupharma.com

CEO

Mitchell Shuster Steiner

Incorporated in

Wisconsin

Location

Florida

Fiscal year end

Sep 30

Sector

Health Technology > Pharmaceuticals: Major

Industry (SEC)

Pharmaceutical Preparations

Pfizer • Merck & Co. • Allergan • Johnson & Johnson • Abbott Laboratories • Teva Pharmaceutical Industries • Bristol Myers Squibb • ELI LILLY & Co • Warner Chilcott • AbbVie ...

Former names

Female Health Co

SEC CIK

0000863894

Corporate docs

Articles of Incorporation & Bylaws

IRS number

391144397

VERU stock data

S&P 500

1M 1Y 2Y 5Y

FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings

Securities sold

Number of investors

Company financial data Financial data

Chart VERU financial data

Quarter (USD)	Mar 20	Dec 19	Sep 19	Jun 19
Revenue	9.94M	10.58M	8.73M	9.73M
Net income	-810.51K	-3.31M	-3.06M	-2.77M
Diluted EPS	-0.01	-0.05	-0.05	-0.04
Net profit margin	-8.15%	-31.24%	-35.06%	-28.52%
Operating income	-299.68K	-1.78M	-1.46M	-1.84M
Net change in cash				2.14M
Cash on hand				8.04M
Cost of revenue	2.51M	3.31M	2.9M	3.16M

Annual (USD)	Sep 19	Sep 18	Sep 17	Sep 16
Revenue	31.8M	15.86M	13.66M	22.13M
Net income	-12.02M	-23.94M	-6.61M	344.73K
Diluted EPS	-0.19	-0.44	-0.25	0.01
Net profit margin	-37.79%	-151%	-48.42%	1.56%
Operating income	-6.44M	-20.87M	-8.49M	3.02M
Net change in cash		481.91K	892.52K	-1.72M
Cash on hand		3.76M	3.28M	2.39M
Cost of revenue	10.15M	7.09M	6.64M	8.78M

Financial data from Veru earnings reports

Recent insider trades

VERU insider ownership history Insider history

Date	Owner	Security	Transaction	Code	$Price	#Shares	$Value	#Remaining
21 Feb 20	Fisch Harry	Common Stock	Buy	Aquire P	4.47	1,000	4.47K	859,025
20 Feb 20	Fisch Harry	Common Stock	Buy	Aquire P	4.51	1,000	4.51K	858,025
19 Feb 20	Jesus Socorro	Common Stock	Buy	Aquire P	4.27	5,000	21.35K	32,500
19 Dec 19	Jesus Socorro	Common Stock	Buy	Aquire P	2.7999	5,000	14K	27,500
5 Dec 19	Steiner Mitchell Shuster	Common Stock	Sell	Dispose S	2.221	16,590	36.85K	7,434,767
4 Dec 19	Steiner Mitchell Shuster	Common Stock	Sell	Dispose S	2.199	8,410	18.49K	7,451,357

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q3 2019

VERU institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0	NaN%
Opened positions	0	0	NaN%
Closed positions	0	0	NaN%
Increased positions	0	0	NaN%
Reduced positions	0	0	NaN%

13F shares	Current	Prev Q	Change
Total value	0	0	–
Total shares	0	0	–
Total puts	0	0	–
Total calls	0	0	–
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Canada • Allergan • Opexa Therapeutics • HCI • Path • Allergan

Risks

COVID-19 and its impact on the economic environment and capital markets could adversely affect our access to capital when needed.
We may not be entitled to forgiveness of our recently received PPP Loan, and our application for the PPP Loan could in the future be determined to have been impermissible or could result in damage to our reputation.

Management Discussion

The Company generated net revenues of $9.9 million and net loss of $0.8 million, or $(0.01) per basic and diluted common share, for the three months ended March 31, 2020, compared to net revenues of $7.0 million and net loss of $4.0 million, or $(0.07) per basic and diluted common share, for the three months ended March 31, 2019. Net revenues increased 43% year over year.
FC2 net revenues represented 96% of total net revenues for the three months ended March 31, 2020. FC2 net revenues increased 39% year over year. There was a 30% decrease in total FC2 unit sales and an increase in FC2 average sales price per unit of 98%. The principal factor for the increase in the FC2 average sales price per unit compared to prior year was the increase in net revenues in the U.S. prescription channel. The Company experienced an increase of 168% in FC2 net revenues in the U.S. prescription channel and a decrease of 40% in FC2 net revenues in the global public sector.
Cost of sales increased to $2.5 million in the three months ended March 31, 2020 from $2.4 million in the three months ended March 31, 2019 primarily due to an increase in labor, transportation, and equipment maintenance costs.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Acute, advantage, alive, altogether, antitumor, antiviral, attempt, BARDA, baseline, binding, Biomedical, bone, broad, burden, candidate, certainty, chemotherapy, civil, claim, clarity, clear, colchicine, combat, combating, commerce, commitment, committing, contact, controversy, criminal, CT, CTAP, cycle, cytokine, DARPA, death, decided, declared, decline, demonstrated, Department, depolymerization, diarrhea, discontinuation, discontinue, dissipate, distancing, diversion, diverted, documentation, documented, economy, efficacy, effort, eligibility, eligible, emerged, emergency, encounter, endpoint, entirety, escalated, exemption, expedite, faith, fallen, False, fatigue, forced, forgivable, forgiven, freely, furlough, good, headcount, high, hospital, hospitalization, hospitalized, imaging, impede, impermissible, important, imposed, imposing, indirectly, induced, ineligible, infection, inhibit, interpretation, interrupted, interruption, intracellular, job, lack, lender, long, longevity, mandatory, maturity, mechanical, media, median, microtubule, mild, mitigate, monitor, monitoring, monthly, mortality, mortgage, MTD, national, nausea, neurotoxicity, neutropenia, obsolete, ordinal, oversee, pandemic, Paycheck, payroll, penalty, permission, pivotal, postpone, PPP, prechemotherapy, preliminary, prioritize, prioritized, prioritizing, proceeding, progression, proportion, PSA, pulmonary, pursuit, randomized, rapid, rapidly, RECIST, recommended, recruit, recruiting, recruitment, reevaluate, refuse, rely, reopen, reopening, repay, run, safety, salary, SBA, scale, schedule, scientific, Secondary, serum, sheath, sheltering, site, situation, social, soft, Solid, spiked, spread, stable, stopping, storm, strain, strong, suffering, supplier, surgical, surveillance, suspended, syndrome, temporarily, therapeutic, threat, tissue, tolerated, trafficking, tumor, unexpected, unintended, unprecedented, unwilling, urgent, ventilation, viral, vomiting, worker, workforce, worsen

Removed: exceed, filed, movement, population, realized, region, Ringgit, vulnerable

From filing 10-Q 2020 Q2